


Ts Phan Đăng Bội Linh - Khoa Nội TM

GIỚI THIỆU

Kết quả của các thử nghiệm và nghiên cứu đăng ký đã cho thấy tỉ lệ tử vong dài hạn thấp hơn sau mô bắt cầu nối ĐMV (CABG) so với can thiệp mạch vành qua da (PCI) trong số các bệnh nhân bệnh đa thân ĐMV (multivessel disease). Nhưng những phân tích trước đây chưa đánh giá PCI với stent phủ thuốc thế hệ thứ hai vì cân nhắc có những nghiên cứu mới để trả lời câu hỏi này.



PH NG PHÁP

Trong mt nghiên cu đng ký quan sát, tiến hành so sánh các kt qu nhóm bn nhn bn nh đa thân ĐMV tr i qua ph u bắt cầu (CABG) so v i kt qu tng tng nhng bn nh nhn nhóm PCI s đng stent phủ thuốc everolimus (thế h 2). Kt c c chính là t l t vong do mo i nguyên nhn. Kt c c th phát là t l nh i máu c tim, đt qu và lp i tái thông mạch máu. Vi c đối chng các cấ p điêm phù h p đã đ c s đng đ ta o ra mt nhóm bn nh nhn có các đ c đi m c bn tng tng nhau.




Table 1. Baseline Characteristics before and after Propensity-Score Matching.*						
Characteristic	Before Matching			After Matching		
	PCI (N=16,876)	CABG (N=17,943)	Standardized Difference %	PCI (N=9223)	CABG (N=9223)	Standardized Difference %
Age						
Mean (yr)	65.0±11.2	65.3±10.6	2.4	65.1±11.1	65.1±10.8	0.5
Distribution (%)						
<59 yr	32.2	29.4	6.0	31.2	30.7	0.9
60–69 yr	31.8	33.9	4.4	32.8	33.1	0.6
70–79 yr	25.6	27.5	4.5	26.4	26.0	0.8
≥80 yr	10.4	9.1	4.4	9.6	10.1	1.6
Sex (%)						
Male	70.8	74.2	7.7	72.6	72.9	0.7
Female	29.2	25.8	7.7	27.4	27.1	0.7
Body-surface area (m ²)	2.03±0.27	2.04±0.27	<0.1	2.04±0.27	2.04±0.27	0.2
Hispanic ethnic group (%)†	12.4	8.9	11.4	11.0	11.0	0.0
Race (%)†						
White	76.7	85.1	21.6	81.0	81.5	1.2
Black	11.2	7.7	12.1	9.3	9.1	0.7
Other	12.1	7.2	16.8	9.7	9.4	0.9
Diabetes (%)	39.0	40.6	3.1	39.0	39.5	1.2
Ejection fraction (%)						
<20%	0.6	1.5	9.7	0.8	0.8	0.5
20–29%	2.9	6.5	16.8	4.1	4.4	1.4
30–39%	5.0	11.4	23.8	7.2	7.4	0.6
40–49%	12.2	19.0	18.7	15.7	15.4	1.0
≥50%	74.5	61.3	28.5	71.7	71.6	0.4
Data missing	4.8	0.3	29.1	0.5	0.5	0.5
Previous myocardial infarction (%)						
1–7 Days before treatment	15.2	18.5	8.6	17.0	16.8	0.4
8–14 Days before treatment	1.2	5.2	23.0	2.0	2.0	0.5
15–20 Days before treatment	0.3	1.0	8.9	0.4	0.5	1.6
>20 Days before treatment	17.5	22.4	12.1	19.5	19.5	0.1
None	65.8	53.0	26.3	61.2	61.1	0.1
Cerebrovascular disease (%)	2.4	7.6	24.1	3.6	3.8	1.0
Peripheral arterial disease (%)	8.6	11.6	9.9	9.6	9.8	0.5
COPD (%)	5.3	12.5	25.4	7.6	7.7	0.4
Congestive heart failure (%)						
None	93.9	85.2	28.8	91.3	91.2	0.4
At current admission	3.7	11.7	30.4	5.8	6.0	0.8
Before current admission	2.4	3.1	4.4	2.8	2.7	0.5

Table 1. (Continued.)						
Characteristic	Before Matching			After Matching		
	PCI (N=16,876)	CABG (N=17,943)	Standardized Difference %	PCI (N=9223)	CABG (N=9223)	Standardized Difference %
Malignant ventricular arrhythmia (%)	0.4	0.8	6.3	0.5	0.6	0.9
Renal failure (%)						
Requiring dialysis	2.5	2.8	2.3	2.4	2.7	1.5
Creatinine level in patients not requiring dialysis‡						
<1.3 mg/dl	78.2	73.6	10.9	77.1	76.4	1.8
1.3–1.5 mg/dl	12.2	13.4	3.8	12.6	13.0	1.1
1.6–2.0 mg/dl	5.0	6.7	6.9	5.4	5.5	0.3
>2.0 mg/dl	2.1	3.5	8.4	2.4	2.5	0.5
No. of diseased vessels (%)						
2						
With proximal LAD artery	18.8	17.8	2.7	26.3	25.9	0.8
Without proximal LAD artery	55.1	15.7	90.5	29.5	29.2	0.5
3						
With proximal LAD artery	8.6	35.5	68.7	15.3	15.2	0.4
Without proximal LAD artery	17.5	31.0	32.0	28.9	29.6	1.6
Prior PCI (%)	31.7	18.0	32.0	24.5	24.1	1.0

* Plus–minus values are means $\pm$ SD. The standardized differences are reported as percentages; a difference of less than 10.0% indicates a relatively small imbalance. CABG denotes coronary-artery bypass grafting, COPD chronic obstructive pulmonary disease, LAD left anterior descending, and PCI percutaneous coronary intervention.

† Race and ethnic group were self-reported.

‡ To convert the values for creatinine to micromoles per liter, multiply by 88.4.

Table 2. Risk of Primary and Secondary Outcomes in the Propensity-Score-Matched Cohort.*

Outcome	No. of Patients with Event	Event Rate %/yr	Hazard Ratio (95% CI)	P Value
Death				
PCI	768	3.10	1.04 (0.93–1.17)	0.50
CABG	815	2.86	Reference	
Myocardial infarction				
PCI	462	1.87	1.51 (1.29–1.77)	<0.001
CABG	322	1.13	Reference	
Stroke				
PCI	178	0.72	0.62 (0.50–0.76)	<0.001
CABG	277	0.97	Reference	
Revascularization				
PCI	1793	7.25	2.35 (2.14–2.58)	<0.001
CABG	883	3.10	Reference	

* The propensity-score-matched cohort included 9223 patients in the PCI group and 9223 patients in the CABG group.




Figure 2. Cumulative Risks of the Study Outcomes in the Matched Cohort.

In each panel, the inset shows the same data on an enlarged y axis.